- UK Life Sciences Vision sets 10-year strategy for sector to build on successes of COVID-19 response and accelerate delivery of innovations to patients
- mission-led approach to solve some of the biggest healthcare problems of our generation, including cancer and dementia
- launch of Life Sciences Investment Programme brings total amount of funding available to UK’s most promising life sciences companies to £1 billion
The remarkable response of the UK’s world class life sciences sector to COVID-19 will be used as a blueprint to accelerate the delivery of life-changing innovations to patients, as part of the government’s new UK Life Sciences Vision published today (Wednesday 7 July).
Today’s new UK Life Sciences Vision, co-developed with businesses and experts in the field, sets out a mission-led approach with bold ambition for the next decade to ensure scientific excellence, partnered with the dynamism of industry, is replicated to assist the NHS in solving the most pressing health challenges of our generation now and in the future.
The Vision outlines 7 critical healthcare missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia.
These missions will focus on preventing, diagnosing, monitoring and treating disease early, using innovative clinical trials to develop breakthrough products and treatments quickly to help save lives, and accelerating the development and adoption of new drugs, diagnostics, medical technology and digital tools.
The missions are:
- Accelerating the pace of studies into novel dementia treatment
- Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines
- Sustaining the UK’s position in vaccine discovery, development and manufacturing
- Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity
- Reducing mortality and morbidity from respiratory disease in the UK and globally
- Addressing the underlying biology of ageing
- Increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them
Prime Minister Boris Johnson said:
We are indebted to the ingenuity of UK life sciences and its pioneers, with the discovery of the Oxford-AstraZeneca vaccine and the seamless collaboration between our scientists, industry, regulators and NHS saving millions of lives during the pandemic.
We must make sure this is the norm and use this new way of working to search for life-changing breakthroughs against diseases such as cancer, dementia and obesity, as we have done with COVID.
That’s why we are setting out our new Life Sciences Vision to bottle the formula we have developed to tackle COVID and improve health outcomes for patients across the board in the UK, and secure jobs and investment in the process as we build back better.
Business Secretary Kwasi Kwarteng said:
The UK life sciences sector has been a beacon of hope over the past year and a half, developing diagnostics and life-saving vaccines at remarkable speed to secure our route out of the pandemic.
This ambitious strategy sets out how we can replicate this same scientific excellence and agility to meet today’s greatest health challenges, doing with cancer, dementia and obesity what we did with this virus – gaining the upper hand with brilliant science.
Crucially, we’re going to build a pro-enterprise environment where our life sciences firms can access the finance to grow, are incentivised to onshore manufacturing, and can commercialise breakthrough products right here in the UK - rather than elsewhere – as we cement the UK’s position as a science superpower.
The UK’s life sciences sector has been at the centre of the country’s efforts to combat COVID-19 – from the development of the Oxford-AstraZeneca vaccine to the world leading RECOVERY trial identifying safe and effective therapeutics.
The Vision looks to emulate the successes of the UK Vaccines Taskforce – harnessing private sector expertise and removing unnecessary bureaucracy so that the UK’s most knowledgeable industry leaders can tackle future healthcare challenges at speed and at risk – with the aim of changing people’s lives for the better.
It will ensure that the UK benefits from new regulatory freedoms and opportunities now that we have left the European Union. The Medicines & Healthcare products Regulatory Agency (MHRA) will be able to act as an independent, sovereign regulator with great agility and with a focus on getting vaccines, drugs, and technologies to patients as safely and quickly as possible.
Addressing the most pressing healthcare challenges of our generation now and in the future will be an important part of the government’s levelling up agenda, helping to reduce health inequalities and improving out comes for patients in every corner of the UK.
Health and Social Care Secretary, Sajid Javid, said:
We have made immense strides in health research over the past year - the discovery of the use of dexamethasone and our vaccine rollout have been crucial to saving hundreds of thousands of lives and tackling COVID-19.
It’s crucial we continue to harness this enthusiasm and innovation, and map out a new route as we build back better. Today’s bold vision commits to putting the lessons we’ve learnt into action to transform the UK into a life sciences superpower.
Life Sciences Minister Nadhim Zahawi said:
Through this pandemic, we have turned to the brilliance of our UK life sciences sector which time after time has stepped up and done the country proud – from developing life-saving vaccines to identifying variants through world class genome sequencing.
We want to bottle up this scientific brilliance, and the Life Sciences Vision provides a roadmap for how we apply this innovation at the heart of our NHS helping to solve major health challenges such as dementia and obesity – all while ensuring the UK remains a global leader in life sciences.
Minister for Innovation, Lord Bethell said:
The pandemic showed the UK life sciences industry tackling the world’s most challenging health problems, and winning. But there is more to do. This vision builds on the successes on vaccines, therapeutics and diagnostics, and lays down a clear plan for turning our great science into effective treatments delivering better healthcare and creating jobs. It is based on our muscular private industry, the research insight of our universities and, critically, the unique power of the NHS to mobilise clinical trials and deploy innovation at speed and scale.
The Life Sciences Vision is the first sectoral publication to build on the Plan for Growth, which sets out plans for the UK to stand as a world-leading centre for the development of brilliant ideas, innovation in industry, and jobs for the future.
Sir John Bell, Professor at Oxford University and Sir Jonathan Symonds, Chair, GSK chaired the Vision’s External Advisory Board to ensure the breadth and depth of the sector were represented in the Vision’s development. The board included representatives such as Dame Kate Bingham to help translate the success of the Vaccines Taskforce to other disease challenges.
Professor Sir John Bell, University of Oxford, Co-chair of the External Advisory Group said:
There is now a race to become one of the world leaders in the growth of Life Sciences as an industrial sector. We have demonstrated throughout the COVID pandemic how effective we can be when industry, academia, government, charities and the NHS all work together. If we continue to work as effectively together we are very likely to bring great benefits to patients and also to grow our economy at pace.
Sir Jonathan Symonds, Chairman, GSK, Co-chair of the External Advisory Group said:
Addressing the healthcare challenges we face today requires a life sciences strategy of bold ideas backed by evidence and data. The Vision we are setting out provides a new blueprint for how government, the NHS and industry can work together to deliver the next generation of therapies, diagnostics and insights to improve patient health, to create a truly outstanding environment for healthcare companies to invest and grow, and to reinforce the UK’s position as a leading global destination for medical scientific research and investment.
Central to the Life Sciences Vision is a focus on cultivating a business environment in which UK life sciences firms can access finance to innovate and grow, are regulated in an agile and efficient way, and are incentivised to onshore manufacture and commercialise their products in the UK.
To support this ambition, the government has today also launched its Life Sciences Investment Programme, a £200 million government investment that will unlock the potential of innovative UK life sciences companies so that they can grow their operations and create high-skilled jobs in the UK.
The programme will leverage further private sector investment and support the development of a world leading UK life sciences venture capital ecosystem. The investment will be delivered through British Patient Capital, part of the government-owned British Business Bank, which will allocate the £200 million to specialist funds.
In a further boost to the sector, British Patient Capital has recently agreed a collaboration with Abu Dhabi’s Mubadala Investment Company, one of the world’s leading sovereign investors. Under this partnership, facilitated by the Office for Investment, Mubadala has committed to invest £800 million in the UK life sciences industry and will work with British Patient Capital to identify sector trends and investment opportunities.
In total, this means £1 billion of new funding is available for the UK’s most promising life sciences companies, with the potential to crowd in further funding from other investors.
The Life Sciences Investment Programme will have access to a scientific advisory panel composed of leading industry figures, chaired by Life Sciences Champion Professor Sir John Bell. The panel will share insight on key scientific trends.
The life sciences sector is critical to the UK’s health, wealth and resilience, employing more than 250,000 people and generating an £80 billion turnover each year in the UK. A key theme of the Vision is to support the sector to grow, attracting investment and creating high skilled jobs across the UK.
Notes to editors
The Life Sciences Vision has been developed in partnership with the sector and builds on the success of the 2017 Life Sciences Industrial Strategy.
The Vision will be followed by detailed implementation plans later in the year, which will run alongside the Comprehensive Spending Review process.
Additional quotes from stakeholders
Lord David Prior, Chair of NHS England said:
Life sciences are a game changer for the UK’s collective health. Through innovation and technological advances, we will diagnose, treat, cure and prevent a much wider range of disease than is currently possible, and life sciences are an invaluable weapon for the NHS in the fight against disease - these advances will change society.
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said:
The BIA’s focus will be to increase the expert pool of UK based capital needed for innovative UK life science firms to grow to scale. This will enable UK investors and pension savers, to secure the economic benefit from this burgeoning golden age for UK life sciences while at the same time enabling NHS patients to secure the health benefit of global biotech innovation.
I am pleased that the Vision identifies 4 preconditions for success which must be met over the next decade, giving industry and government clear goals. Working together, we must simplify the governance and oversight of NHS health data, make the NHS an Innovation Partner, increase UK R&D spend and broaden UK access to finance to scale at pace to deliver this rightly ambitious vision.
Roland Diggelmann, CEO, Smith+Nephew said:
We welcome this recognition of the importance of the UK’s life sciences sector, including our world-class medtech expertise. The UK has a unique healthcare ecosystem where we believe innovation can flourish and the Vision is an important step towards this. As the UK’s largest medtech company, Smith+Nephew looks forward to working in partnership with government and colleagues from across the healthcare sector to build on the Vision to benefit the NHS, clinicians, patients and the economy.
Peter Ellingworth, CEO, Association of British HealthTech Industries said:
Building on the role that global and local healthtech companies played in addressing the challenges of the COVID pandemic, this vision sets out an ambitious approach that will require close collaboration between industry, government and the NHS to ensure it brings a meaningful impact for patients and an efficient health service. Central to improving end-to-end patient pathways will be diagnostic and digital technologies, and investment decisions must recognise this. This will not only enable the success of Integrated Care Systems, but will deliver a more sustainable healthcare system in the future.
Michelle Mitchell, Chief Executive of Cancer Research UK said:
Just as science is our route out of the pandemic, science holds the key to beating cancer. If we can apply a similar pace and scale of research and innovation as we saw with COVID-19 to diseases like cancer, we can make a huge difference for the 1000 people diagnosed with cancer every day in the UK.
Developing the Life Sciences Vision together has been the first step of what I hope will see cancer research strengthened and bring improvements for people with cancer. We’re pleased to see the commitments made to boosting early diagnosis and treatment for cancer, areas that we have pioneered as we know they will make a big impact for patients.
We look forward to working with government and the life sciences sector to make this vision a reality. Backed by the right investment, this vision will set the UK apart as a world leader in life sciences and cancer research, which will drive scientific innovation and, ultimately, save lives.
Sir Menelas Pangalos, Executive Vice President & President BioPharmaceuticals R&D, AstraZeneca said:
Future development of the UK’s life sciences sector, and the health and economic benefits that can bring, hinges on hard-wiring innovation across the entire healthcare ecosystem. From academic research, through development, manufacture, supply and the adoption of new medicines and technologies, this Life Sciences Vision embraces just such a holistic approach. Translating ambition to reality, to benefit patients, advance science and grow our economy must now be our shared, urgent mission.
Professor Sir Nilesh Samani, Medical Director at the British Heart Foundation, said:
Cardiovascular diseases including heart attacks and strokes are still responsible for 1 in 4 deaths in the UK, and growing numbers of people are living with them. These diseases represent one of the most pressing health challenges we face.
The life science sector’s response to the pandemic has shown that unimaginable progress is possible when the research community unites behind a common goal and unleashes the full potential and capability that exists in the UK across NHS, academia and industry, supported by government and medical research charities. By bottling this approach, this Vision could set the stage for the rapid development of new ways of preventing and treating heart diseases as well as the conditions that cause them, such as obesity.
Richard Torbett, Chief Executive, the Association of the British Pharmaceutical Industry said:
This is an ambitious statement about how the UK can become a life sciences superpower.
We’ve seen just how important the partnership between industry, the government and the NHS has been to the response to the pandemic, and we need to take the same approach if we are going to make the UK a global hub for life sciences.
By putting the NHS at the centre of the vision, we can also deliver for patients and make the UK the best place in the world to research, develop, manufacture, and use the latest medicines and vaccines.